165 related articles for article (PubMed ID: 25711516)
21. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
22. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.
Meyers K; Cogan DA; Burke J; Arenas R; Balestra M; Brown NF; Chen Z; Cerny MA; Clifford HE; Colombo F; Fader L; Frederick KS; Guo X; Goldberg D; Hornberger KR; Kugler S; Lord J; Marshall DR; Moss N; Parmentier JH; Richman JR; Schmenk J; Weldon SM; Yu M; Zhang M
Bioorg Med Chem Lett; 2018 Mar; 28(5):979-984. PubMed ID: 29254646
[TBL] [Abstract][Full Text] [Related]
23. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets.
Hakki T; Bernhardt R
Pharmacol Ther; 2006 Jul; 111(1):27-52. PubMed ID: 16426683
[TBL] [Abstract][Full Text] [Related]
24. Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis.
Gobbi S; Hu Q; Zimmer C; Engel M; Belluti F; Rampa A; Hartmann RW; Bisi A
J Med Chem; 2016 Mar; 59(6):2468-77. PubMed ID: 26938274
[TBL] [Abstract][Full Text] [Related]
25. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
[TBL] [Abstract][Full Text] [Related]
26. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
[TBL] [Abstract][Full Text] [Related]
27. Imidazopyridyl compounds as aldosterone synthase inhibitors.
Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
[TBL] [Abstract][Full Text] [Related]
28. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
Cerny MA; Csengery A; Schmenk J; Frederick K
J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
[TBL] [Abstract][Full Text] [Related]
29. Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.
Meguro M; Miyauchi S; Kanao-Arisumi Y; Naito S; Suzuki K; Inoue S; Yamada K; Homma T; Chiba K; Nara F; Furuzono S
Bioorg Med Chem; 2024 Jun; 108():117775. PubMed ID: 38851000
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors.
Ferlin MG; Carta D; Bortolozzi R; Ghodsi R; Chimento A; Pezzi V; Moro S; Hanke N; Hartmann RW; Basso G; Viola G
J Med Chem; 2013 Oct; 56(19):7536-51. PubMed ID: 24025069
[TBL] [Abstract][Full Text] [Related]
31. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
Pinto-Bazurco Mendieta MA; Negri M; Hu Q; Hille UE; Jagusch C; Jahn-Hoffmann K; Müller-Vieira U; Schmidt D; Lauterbach T; Hartmann RW
Arch Pharm (Weinheim); 2008 Oct; 341(10):597-609. PubMed ID: 18720339
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17.
Nakamura Y; Kitada M; Satoh F; Maekawa T; Morimoto R; Yamazaki Y; Ise K; Gomez-Sanchez CE; Ito S; Arai Y; Dezawa M; Sasano H
Mol Cell Endocrinol; 2016 Feb; 422():57-63. PubMed ID: 26597777
[TBL] [Abstract][Full Text] [Related]
33. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
[TBL] [Abstract][Full Text] [Related]
34. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics.
Roumen L; Sanders MP; Pieterse K; Hilbers PA; Plate R; Custers E; de Gooyer M; Smits JF; Beugels I; Emmen J; Ottenheijm HC; Leysen D; Hermans JJ
J Comput Aided Mol Des; 2007 Aug; 21(8):455-71. PubMed ID: 17646925
[TBL] [Abstract][Full Text] [Related]
35. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
LaSala D; Shibanaka Y; Jeng AY
Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
[TBL] [Abstract][Full Text] [Related]
36. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
[TBL] [Abstract][Full Text] [Related]
37. The potential of targeting CYP11B.
Bernhardt R
Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
[TBL] [Abstract][Full Text] [Related]
38. Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1.
Gobbi S; Hu Q; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
Eur J Med Chem; 2017 Oct; 139():60-67. PubMed ID: 28797884
[TBL] [Abstract][Full Text] [Related]
39. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
40. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
Emmerich J; Hu Q; Hanke N; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6022-32. PubMed ID: 23869452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
